← Back to Screener
HCW Biologics Inc. Common Stock (HCWB)
Price$2.07
Value ScoreB
Growth ScoreF
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)-12.97%
Price vs S&P 500 (4W)333.08%
VGM Score38.17
Market Capitalization$13.33M
All Metrics
Book Value / Share (Quarterly)$0.86
P/TBV (Annual)1.11x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-79.94%
Cash Flow / Share (Quarterly)$-1.70
Price vs S&P 500 (YTD)92.98%
Gross Margin (TTM)99.42%
Net Profit Margin (TTM)34.42%
EPS (TTM)$-2.25
10-Day Avg Trading Volume69.09M
EPS Excl Extra (TTM)$-2.25
Revenue Growth (5Y)-57.90%
EPS (Annual)$-3.79
ROI (Annual)-83.14%
Gross Margin (Annual)19.99%
Net Profit Margin (5Y Avg)-3418.02%
Cash / Share (Quarterly)$0.18
Revenue Growth QoQ (YoY)-93.16%
ROA (Last FY)-32.46%
Revenue Growth TTM (YoY)-98.69%
EBITD / Share (TTM)$-0.71
ROE (5Y Avg)-115.76%
Operating Margin (TTM)11.72%
Cash Flow / Share (Annual)$-4.08
P/B Ratio2.31x
P/B Ratio (Quarterly)0.42x
Net Income / Employee (Annual)$-318,400
EV / Revenue (TTM)2.84x
Net Interest Coverage (TTM)-4.76x
ROA (TTM)-8.63%
EPS Incl Extra (Annual)$-3.79
Current Ratio (Annual)0.11x
Quick Ratio (Quarterly)0.07x
3-Month Avg Trading Volume14.20M
52-Week Price Return-75.31%
Revenue / Employee (TTM)$263,100
Tangible BV / Share (Quarterly)$0.66
P/S Ratio (Annual)245.87x
Asset Turnover (Annual)0.00x
52-Week High$8.75
Operating Margin (5Y Avg)-3324.26%
EPS Excl Extra (Annual)$-3.79
CapEx CAGR (5Y)-29.10%
26-Week Price Return2.96%
Quick Ratio (Annual)0.10x
13-Week Price Return260.00%
Total Debt / Equity (Annual)2.46x
Current Ratio (Quarterly)0.09x
Enterprise Value$18.68M
Revenue / Share Growth (5Y)-25.78%
Asset Turnover (TTM)0.24x
Revenue / Employee (Annual)$2,200
Pretax Margin (Annual)-14677.69%
Cash / Share (Annual)$0.60
3-Month Return Std Dev616.60%
Net Income / Employee (TTM)$-91,600
EBITDA Interim CAGR (5Y)0.07%
ROE (Last FY)-287.90%
Net Interest Coverage (Annual)0.99x
EPS Basic Excl Extra (Annual)$-3.79
Receivables Turnover (TTM)81.03x
Total Debt / Equity (Quarterly)1.14x
EPS Incl Extra (TTM)$-2.25
Receivables Turnover (Annual)0.18x
ROI (TTM)38.26%
P/S Ratio (TTM)2.03x
Pretax Margin (5Y Avg)-3418.02%
Revenue / Share (Annual)$0.03
Tangible BV / Share (Annual)$1.04
Price vs S&P 500 (52W)-103.52%
Year-to-Date Return103.91%
5-Day Price Return-31.49%
EPS Normalized (Annual)$-3.79
ROA (5Y Avg)-55.06%
Net Profit Margin (Annual)-14677.69%
Month-to-Date Return320.20%
Cash Flow / Share (TTM)$-0.52
EBITD / Share (Annual)$-3.56
Operating Margin (Annual)-14201.49%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-61.80%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-2.25
P/TBV (Quarterly)1.75x
P/B Ratio (Annual)0.95x
Pretax Margin (TTM)39.45%
Book Value / Share (Annual)$0.84
Price vs S&P 500 (13W)250.25%
Beta2.25x
Revenue / Share (TTM)$1.21
ROE (TTM)98.31%
52-Week Low$0.25
vGradeB
gGradeF
mGradeC
vgmGradeD
Show chart for
Earnings Surprise History
Q1 260.37est. -0.45
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
HCWBHCW Biologics Inc. Common Stock | B | F | C | $2.07 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
HCW Biologics is a clinical-stage biopharmaceutical company developing immunotherapies to treat age-related diseases by targeting chronic inflammation. The company uses its proprietary TOBI discovery platform to generate two lead candidates: HCW9218, which neutralizes growth factors and stimulates immune cells, and HCW9302, which activates regulatory T cells to reduce inflammation. This approach targets the inflammation-aging link to potentially extend healthspan across multiple indications.